Data from the recently completed Phase 2 trial of Resunab (JBT-101) for cystic fibrosis (CF) treatment will be…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
Drugs targeting a component of biofilm — the glue-like layer secreted by bacteria in cystic fibrosis (CF) patients’ lungs —…
Researchers at the University of Wisconsin–Madison have developed a technique that makes it possible to watch gene-editing processes in real…
A deeper understanding of how a bacterial enzyme works to degrade the protective layer that surrounds bacteria, helping it to…
The bacterial species Clostridium difficile is often found in the gut of cystic fibrosis (CF) patients, but rarely makes them…
Catabasis Pharmaceuticals’ compound CAT-5571 showed promising effects on CFTR activity (the defective gene/protein in cystic fibrosis) in preclinical models…
Protalix BioTherapeutics’ AIR DNase (alidornase alfa), developed to make mucus in the lungs of cystic fibrosis (CF) patients less…
The bacteria Pseudomonas aeruginosa, which settle in the lungs of most cystic fibrosis (CF) patients, destroy the lungs by perpetuating…
People with more severe cystic fibrosis-causing gene mutations tend to have poorer mental health as they age, an effect mediated…
Researchers may have come one step closer to more effective treatments against Pseudomonas aeruginosa growing in layers known as harmful…